Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed Or Refractory Diffuse Large B-cell Lymphoma

Posted on the 05 November 2020 by Juan Sanchez @times_european

… subcutaneous epcoritamab, a fully-human IgG1-bispecific antibody designed … territories including the U.S., Europe and Japan, Kesimpta® ( … the U.S. and Europe for the treatment of … our patents and proprietary rights, our relationships with affiliated …

The post Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma first appeared on TheEuropeanTimes.INFO.